» Articles » PMID: 38831291

A Randomized Control Trial to Compare Mortality in Recipients of Leucoreduced and Non-leucoreduced Whole Blood Transfusion in Patients with Cancer in Uganda

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2024 Jun 3
PMID 38831291
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mortality benefit of transfusion with leucoreduced whole blood has not been demonstrated in the sub-Saharan Africa (SSA). We compared mortality in patients with cancer transfused with leucoreduced and non-leucoreduced whole blood in a SSA setting.

Methods: An open-label randomized controlled trial was conducted at the Uganda Cancer Institute where participants were randomized in a 1:1 ratio into the leucoreduced and non-leucoreduced whole blood transfusion arms. Leucocyte filtration of whole blood was performed within 72 h of blood collection. Patients aged ≥ 15 years who were prescribed blood transfusion by the primary physicians were eligible for study enrolment. Mortality difference was analyzed using intention-to-treat survival analysis and cox proportional hazard model was used to analyze factors associated with mortality.

Results: There were 137 participants randomized to the leucoreduced and 140 to the non-leucoreduced arms. Baseline characteristics were similar between the two arms. The median number of blood transfusions received was 1 (IQR, 1-3) unit and 2 (IQR, 1-3) units in the leucoreduced and non-leucoreduced arms respectively, p = 0.07. The 30-day mortality rate in the leucoreduced arm was 4.6% (95% CI, 2.1-10) and was 6.2% (95% CI, 3.2-12.1) in the non-leucoreduced arm (p = 0.57), representing an absolute effect size of only 1.6%. Increasing age (HR = 0.92, 95% CI, 0.86-0.98, p = 0.02) and Eastern Co-operative Oncology Group (ECOG) performance score of 1 (HR = 0.03, 95% CI, 0.00-0.31, p < 0.01) were associated with reduced 30-day mortality.

Conclusions: The study failed to demonstrate mortality difference between cancer patients transfused with leucoreduced and non-leucoreduced whole blood. Although this study does not support nor refute universal leucoreduction to reduce mortality in patients with cancer in SSA, it demonstrates the feasibility of doing transfusion RCTs in Uganda, where a multi-center trial with an appropriate sample size is needed.

Trial Registration: Pan African Clinical Trial Registry, https://pactr.samrc.ac.za/ (PACTR202302787440132). Registered on 06/02/2023.

References
1.
Okello C, Shih A, Angucia B, Kiwanuka N, Heddle N, Orem J . Mortality and its associated factors in transfused patients at a tertiary hospital in Uganda. PLoS One. 2022; 17(9):e0275126. PMC: 9499229. DOI: 10.1371/journal.pone.0275126. View

2.
Paglino J, Pomper G, Fisch G, Champion M, Snyder E . Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2003; 44(1):16-24. DOI: 10.1046/j.0041-1132.2004.00608.x. View

3.
Blumberg N, Zhao H, Wang H, Messing S, Heal J, Lyman G . The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007; 47(4):573-81. DOI: 10.1111/j.1537-2995.2007.01158.x. View

4.
Bilgin Y, Brand A . Transfusion-related immunomodulation: a second hit in an inflammatory cascade?. Vox Sang. 2009; 95(4):261-71. DOI: 10.1111/j.1423-0410.2008.01100.x. View

5.
Bowden R, Slichter S, Sayers M, Weisdorf D, Cays M, Schoch G . A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995; 86(9):3598-603. View